Skip to content
Insilico Medicine
-
AI drug developer Insilico Medicine secures US10M deal for Parkinson’s treatment
Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.